Biotech · Public company · Purchase, NY, US
Cognition Therapeutics Inc
Ticker CGTX · SEC CIK 0001455365
Track this companyFree. Adds Cognition Therapeutics Inc to your Dealase workspace and tells you when its record changes.
Clinical trials91 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline9
- Active Comparator CT1812Phase 2 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Active Treatment- CT1812 100 mgPhase 2 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Active Treatment- CT1812 300 mgPhase 2 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CT1812Phase 2 · Mild to Moderate Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CT1812Phase 2 · Dementia With Lewy BodiesClinicalTrials.gov · fetched Nov 12, 2026
- CT1812Phase 2 · Early Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- 300 mg [C14] CT1812Phase 1 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CT1812Phase 1 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- zervimesineDementia With Lewy BodiesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseasePHASE2 · ACTIVE_NOT_RECRUITING · started Jun 28, 2023ClinicalTrials.gov NCT05531656 · fetched Nov 12, 2026
- Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).PHASE2 · TERMINATED · started Jun 16, 2023ClinicalTrials.gov NCT05893537 · fetched Nov 12, 2026
- Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesPHASE2 · COMPLETED · started May 19, 2022ClinicalTrials.gov NCT05225415 · fetched Nov 12, 2026
- Study to Assess the Pharmacokinetics of CT1812 in Older Healthy VolunteersPHASE1 · COMPLETED · started Feb 15, 2022ClinicalTrials.gov NCT05248672 · fetched Nov 12, 2026
- Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male SubjectsPHASE1 · COMPLETED · started Dec 31, 2021ClinicalTrials.gov NCT05225389 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.PHASE2 · COMPLETED · started Oct 10, 2018ClinicalTrials.gov NCT03507790 · fetched Nov 12, 2026
- Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's DiseasePHASE1 · COMPLETED · started May 30, 2018ClinicalTrials.gov NCT03522129 · fetched Nov 12, 2026
- Effect of CT1812 Treatment on Brain Synaptic DensityPHASE1_PHASE2 · COMPLETED · started Mar 28, 2018ClinicalTrials.gov NCT03493282 · fetched Nov 12, 2026
- Expanded Access Program for CT1812 (Zervimesine)NO_LONGER_AVAILABLEClinicalTrials.gov NCT06961760 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Oct 22, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 7, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 24, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 18, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 4, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 21, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 8, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 26, 2026 · fetched Nov 12, 2026
NIH awards3
- Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 MonthsFiscal year 2026 · $16.5MNIH RePORTER 5R01AG065248-05 · fetched Nov 12, 2026
- Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 MonthsFiscal year 2025 · $12MNIH RePORTER 5R01AG065248-04 · fetched Nov 12, 2026
- Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 MonthsFiscal year 2024 · $13.1MNIH RePORTER 5R01AG065248-03 · fetched Nov 12, 2026